RecruitingPhase 1NCT05018819
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for CP
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Cerebral Palsy
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment
15 participants
Start Date
Feb 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Cerebral Palsy
Eligibility
Inclusion Criteria1
- Diagnosis of Cerebral Palsy
Exclusion Criteria9
- Active infection
- Active cancer
- Chronic multisystem organ failure
- Pregnancy
- Clinically significant Abnormalities on pre-treatment laboratory evaluation
- Medical condition that would (based on the opinion of the investigator) compromise patient's safety
- Previous organ transplant
- Seizure disorder
- Hypersensitivity to sulfur
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALAlloRx
cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05018819
Related Trials
Pediatric Outcomes and Recovery With Peri-Operative Iron Supplement Evaluation
NCT070952441 location
Evaluation of Brain MRI Changes in Cerebral Palsy Patients
NCT074336471 location
Assessing Intellectual and Motor Outcomes in High-risk Infants
NCT068575394 locations
BCI@Home: Brain Computer Interface Solutions to Enable Youth Living With Severe Disabilities
NCT070733782 locations
Cerebral Palsy and the Study of Brain Activity During Motor Tasks
NCT018297241 location